Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Earns Buy Rating from Robert W. Baird

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reissued by equities research analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday, October 17th. They currently have a $101.00 price objective on the biotechnology company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 82.09% from the company’s current price.

A number of other research analysts have also recently issued reports on SRPT. Leerink Swann reissued an “outperform” rating and set a $66.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, September 30th. Instinet reissued a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. J P Morgan Chase & Co reissued a “hold” rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, July 27th. Finally, BidaskClub cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.59.

Sarepta Therapeutics (NASDAQ:SRPT) traded up $2.01 during trading hours on Tuesday, hitting $55.47. 2,251,001 shares of the stock traded hands, compared to its average volume of 2,110,000. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $57.29. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The firm had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. During the same period last year, the company posted ($0.95) EPS. research analysts forecast that Sarepta Therapeutics will post -3.28 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Earns Buy Rating from Robert W. Baird” was posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/sarepta-therapeutics-srpt-buy-rating-reaffirmed-at-robert-w-baird/1721595.html.

In related news, SVP Shamim Ruff sold 11,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total transaction of $575,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its holdings in Sarepta Therapeutics by 1.4% during the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 129 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares in the last quarter. Advisor Group Inc. lifted its holdings in Sarepta Therapeutics by 3.2% during the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 326 shares in the last quarter. Legal & General Group Plc lifted its holdings in Sarepta Therapeutics by 3.9% during the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 663 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Sarepta Therapeutics by 0.8% during the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock valued at $3,703,000 after purchasing an additional 818 shares in the last quarter. Institutional investors own 65.58% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.